Abstract
Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
CNS & Neurological Disorders - Drug Targets
Title: Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
Volume: 9 Issue: 5
Author(s): Caitlin M. White, Sunggoan Ji, Huan Cai, Stuart Maudsley and Bronwen Martin
Affiliation:
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
Abstract: Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Export Options
About this article
Cite this article as:
M. White Caitlin, Ji Sunggoan, Cai Huan, Maudsley Stuart and Martin Bronwen, Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361595
DOI https://dx.doi.org/10.2174/187152710793361595 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Information Sharing During Visual Short-Term Memory Binding Yields a Memory Biomarker for Familial Alzheimer's Disease
Current Alzheimer Research Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Editorial (Thematic Issue: Treating Major Age-Related Diseases in Older and Oldest Old Patients)
Current Pharmaceutical Design Editorial (Thematic Issue: Translational Alzheimer’s Disease Research)
Current Alzheimer Research Editorial
Current Molecular Medicine Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development
Current Alzheimer Research Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition The Critical Period for Neuroprotection by Estrogen Replacement Therapy and the Potential Underlying Mechanisms
Current Neuropharmacology